Nasdaq · CIK 0001498382
HURA Kintara Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Nov 14, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Kintara Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Congressional trades
2 trades in HURA disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Laurel M. Lee House · R-FL | Purchase | HURA TuHURA Biosciences, Inc. - Common Stock | $50k to $100k | Jul 13, 2025 | 27 days after the trade |
| Laurel M. Lee House · R-FL | Purchase | HURA TuHURA Biosciences, Inc. - Common Stock | $1,001 to $15k | Nov 25, 2024 | 43 days after the trade |
Transactions
The last 19 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +489,848 | $0.00 | $0 | 489,848 | Nov 14, 2024 |
| Nov 12, 2024 | Bianco James A. Chief Executive Officer | AGrant or award Options (Right to Buy)derivative | +1,065,990 | $0.00 | $0 | 1,065,990 | Nov 14, 2024 |
| Oct 18, 2024 | Yamashita Dennis Chief Scientific Officer | AGrant or award Options (Right to Buy)derivative | +196,790 | $0.00 | $0 | 196,790 | Oct 22, 2024 |
| Oct 18, 2024 | Ng George K director | AGrant or award Options (Right to Buy)derivative | +35,780 | $0.00 | $0 | 35,780 | Oct 22, 2024 |
| Oct 18, 2024 | List Alan director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | MANUSO JAMES S J director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +33,991 | $0.00 | $0 | 33,991 | Oct 22, 2024 |
| Oct 18, 2024 | Bianco James A. Chief Executive Officer | AGrant or award Common Stock | +2,323,307 | $0.00 | $0 | 2,323,307 | Oct 22, 2024 |
| Oct 18, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +68,438 | $0.00 | $0 | 68,438 | Oct 22, 2024 |
| Oct 18, 2024 | MANUSO JAMES S J director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | List Alan director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | Bianco James A. Chief Executive Officer | AGrant or award Options (Right to Buy)derivative | +357,800 | $0.00 | $0 | 357,800 | Oct 22, 2024 |
| Oct 18, 2024 | Ng George K director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +232,570 | $0.00 | $0 | 232,570 | Oct 22, 2024 |
| Oct 18, 2024 | Bianco James A. Chief Executive Officer | AGrant or award Options (Right to Buy)derivative | +71,560 | $0.00 | $0 | 71,560 | Oct 22, 2024 |
| Oct 18, 2024 | Ng George K director | AGrant or award Options (Right to Buy)derivative | +13,553 | $0.00 | $0 | 13,553 | Oct 22, 2024 |
| Oct 18, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +15,744 | $0.00 | $0 | 15,744 | Oct 22, 2024 |
| Oct 18, 2024 | Bianco James A. Chief Executive Officer | AGrant or award Options (Right to Buy)derivative | +191,280 | $0.00 | $0 | 191,280 | Oct 22, 2024 |
| Oct 18, 2024 | Dearborn Dan Chief Financial Officer | AGrant or award Options (Right to Buy)derivative | +66,658 | $0.00 | $0 | 66,658 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bianco James A.Chief Executive Officer
- Dearborn DanChief Financial Officer
- List Alandirector
- MANUSO JAMES S Jdirector
- Ng George Kdirector
- Yamashita DennisChief Scientific Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.